{"title":"氨氯地平改善慢性肾病犬的对称二甲基精氨酸。","authors":"Shohei Morita, Youhei Mochizuki, Takahiro Kondo, Yasuyoshi Matsuda, Takahiro Ohmori, Aritada Yoshimura, Ryuji Fukushima","doi":"10.3389/fvets.2025.1570349","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In canines, chronic kidney disease (CKD) is frequently associated with high blood pressure. Amlodipine is used to treat hypertension in dogs, and we anticipated that amlodipine administration might improve renal function in dogs. However, the effect of amlodipine on canine renal function is unknown. Therefore, this study evaluated changes in symmetric dimethylarginine (SDMA) levels before and after amlodipine administration in pet dogs that had been diagnosed with CKD based on persistently elevated SDMA levels and were being treated with amlodipine alone for any reason. We also conducted a comparative investigation of whether there were any differences in SDMA changes depending on whether these dogs with CKD had hypertension.</p><p><strong>Methods: </strong>This study employed a retrospective design. The study subjects were pet dogs that exhibited persistently elevated SDMA (≥14 μg/dL), were diagnosed with CKD, and were treated with amlodipine. Profile data such as breed, sex, and age, as well as data on blood chemistry tests, blood pressure, heart rate, and echocardiograms before and after amlodipine administration, were collected. Forty-five dogs were included in the study, of which 20 were hypertensive (HT: systolic arterial pressure ≥160 mmHg) and 25 were non-hypertensive (Non-HT: systolic arterial pressure <160 mmHg).</p><p><strong>Results: </strong>Mean SDMA was significantly lower after drug administration compared with before administration in both the HT and Non-HT groups. Moreover, we found that cardiac output (CO) increased in all dogs with CKD treated with amlodipine. Blood pressure measurements showed that the blood pressure decreased in both the HT and Non-HT groups.</p><p><strong>Discussion: </strong>It is believed that the increase in CO due to amlodipine administration increases glomerular filtration rate, which may have led to a decrease in SDMA levels. Based on the rate of decrease in systolic arterial pressure, we considered that amlodipine might decrease blood pressure by a greater amount in patients with higher levels of hypertension. In this study, we showed that amlodipine administration improved SDMA in dogs with CKD regardless of whether they were hypertension. We also showed that amlodipine could be safely used to treat normotensive dogs.</p>","PeriodicalId":12772,"journal":{"name":"Frontiers in Veterinary Science","volume":"12 ","pages":"1570349"},"PeriodicalIF":2.6000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075874/pdf/","citationCount":"0","resultStr":"{\"title\":\"Amlodipine improves symmetric dimethylarginine in dogs with chronic kidney disease.\",\"authors\":\"Shohei Morita, Youhei Mochizuki, Takahiro Kondo, Yasuyoshi Matsuda, Takahiro Ohmori, Aritada Yoshimura, Ryuji Fukushima\",\"doi\":\"10.3389/fvets.2025.1570349\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>In canines, chronic kidney disease (CKD) is frequently associated with high blood pressure. Amlodipine is used to treat hypertension in dogs, and we anticipated that amlodipine administration might improve renal function in dogs. However, the effect of amlodipine on canine renal function is unknown. Therefore, this study evaluated changes in symmetric dimethylarginine (SDMA) levels before and after amlodipine administration in pet dogs that had been diagnosed with CKD based on persistently elevated SDMA levels and were being treated with amlodipine alone for any reason. We also conducted a comparative investigation of whether there were any differences in SDMA changes depending on whether these dogs with CKD had hypertension.</p><p><strong>Methods: </strong>This study employed a retrospective design. The study subjects were pet dogs that exhibited persistently elevated SDMA (≥14 μg/dL), were diagnosed with CKD, and were treated with amlodipine. Profile data such as breed, sex, and age, as well as data on blood chemistry tests, blood pressure, heart rate, and echocardiograms before and after amlodipine administration, were collected. Forty-five dogs were included in the study, of which 20 were hypertensive (HT: systolic arterial pressure ≥160 mmHg) and 25 were non-hypertensive (Non-HT: systolic arterial pressure <160 mmHg).</p><p><strong>Results: </strong>Mean SDMA was significantly lower after drug administration compared with before administration in both the HT and Non-HT groups. Moreover, we found that cardiac output (CO) increased in all dogs with CKD treated with amlodipine. Blood pressure measurements showed that the blood pressure decreased in both the HT and Non-HT groups.</p><p><strong>Discussion: </strong>It is believed that the increase in CO due to amlodipine administration increases glomerular filtration rate, which may have led to a decrease in SDMA levels. Based on the rate of decrease in systolic arterial pressure, we considered that amlodipine might decrease blood pressure by a greater amount in patients with higher levels of hypertension. In this study, we showed that amlodipine administration improved SDMA in dogs with CKD regardless of whether they were hypertension. We also showed that amlodipine could be safely used to treat normotensive dogs.</p>\",\"PeriodicalId\":12772,\"journal\":{\"name\":\"Frontiers in Veterinary Science\",\"volume\":\"12 \",\"pages\":\"1570349\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075874/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Veterinary Science\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://doi.org/10.3389/fvets.2025.1570349\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Veterinary Science","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.3389/fvets.2025.1570349","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
Amlodipine improves symmetric dimethylarginine in dogs with chronic kidney disease.
Introduction: In canines, chronic kidney disease (CKD) is frequently associated with high blood pressure. Amlodipine is used to treat hypertension in dogs, and we anticipated that amlodipine administration might improve renal function in dogs. However, the effect of amlodipine on canine renal function is unknown. Therefore, this study evaluated changes in symmetric dimethylarginine (SDMA) levels before and after amlodipine administration in pet dogs that had been diagnosed with CKD based on persistently elevated SDMA levels and were being treated with amlodipine alone for any reason. We also conducted a comparative investigation of whether there were any differences in SDMA changes depending on whether these dogs with CKD had hypertension.
Methods: This study employed a retrospective design. The study subjects were pet dogs that exhibited persistently elevated SDMA (≥14 μg/dL), were diagnosed with CKD, and were treated with amlodipine. Profile data such as breed, sex, and age, as well as data on blood chemistry tests, blood pressure, heart rate, and echocardiograms before and after amlodipine administration, were collected. Forty-five dogs were included in the study, of which 20 were hypertensive (HT: systolic arterial pressure ≥160 mmHg) and 25 were non-hypertensive (Non-HT: systolic arterial pressure <160 mmHg).
Results: Mean SDMA was significantly lower after drug administration compared with before administration in both the HT and Non-HT groups. Moreover, we found that cardiac output (CO) increased in all dogs with CKD treated with amlodipine. Blood pressure measurements showed that the blood pressure decreased in both the HT and Non-HT groups.
Discussion: It is believed that the increase in CO due to amlodipine administration increases glomerular filtration rate, which may have led to a decrease in SDMA levels. Based on the rate of decrease in systolic arterial pressure, we considered that amlodipine might decrease blood pressure by a greater amount in patients with higher levels of hypertension. In this study, we showed that amlodipine administration improved SDMA in dogs with CKD regardless of whether they were hypertension. We also showed that amlodipine could be safely used to treat normotensive dogs.
期刊介绍:
Frontiers in Veterinary Science is a global, peer-reviewed, Open Access journal that bridges animal and human health, brings a comparative approach to medical and surgical challenges, and advances innovative biotechnology and therapy.
Veterinary research today is interdisciplinary, collaborative, and socially relevant, transforming how we understand and investigate animal health and disease. Fundamental research in emerging infectious diseases, predictive genomics, stem cell therapy, and translational modelling is grounded within the integrative social context of public and environmental health, wildlife conservation, novel biomarkers, societal well-being, and cutting-edge clinical practice and specialization. Frontiers in Veterinary Science brings a 21st-century approach—networked, collaborative, and Open Access—to communicate this progress and innovation to both the specialist and to the wider audience of readers in the field.
Frontiers in Veterinary Science publishes articles on outstanding discoveries across a wide spectrum of translational, foundational, and clinical research. The journal''s mission is to bring all relevant veterinary sciences together on a single platform with the goal of improving animal and human health.